Penumbra, Inc (PEN) Fair Value & Analysis
Healthcare · US · Market cap $12.6B
Penumbra, Inc
PEN · US
Fair value as of: Jun 24, 2026
From 26 valuation models · updated 8 days ago
Fair value updated Jun 24, 2026 — revised from $136.02 to $80.96 (−40.5%) since Jun 23, 2026. Share price −0.1% over the past month.
Price vs Fair Value (12 months)
12‑month range $224.87 – $358.34 · fair‑value band $60.51 – $129.82 · the $317.63 price screens above the $80.96 fair value. As of Jun 24, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Penumbra, Inc (PEN) currently trades at $317.63, while our model-based Fair Value estimate is $80.96 — implying the stock looks roughly 74.5% overvalued today. We read business quality at 70/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).
Over the trailing twelve months, Penumbra, Inc generated revenue of $1.5B at a net margin of 11.8%. Revenue grew 15.6% year over year. It earns a return on equity of 12.7%. Net debt stands at $32.8M. Fundamentals as of Jun 24, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jun 24, 2026. TTM = trailing twelve months.
About the company
Penumbra, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. It offers computer-assisted vacuum thrombectomy; peripheral thrombectomy products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX. It also provides access products, including guide catheters and the Penumbra distal delivery catheters under the Neuron, Neuron MAX, BENCHMARK, BMX, DDC, Access25; MIDWAY, and PX SLIM brands; Penumbra System, an integrated mechanical thrombectomy system comprising reperfusion catheters and separators, the 3D Revascularization device, aspiration tubing, aspiration pump, and other components and accessories under the Penumbra RED, SENDit, JET, ACE, BMX, Max, 3D Revascularization Device, and Penumbra ENGINE brands; and neuro embolization coiling systems that include the …
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Penumbra, Inc reported revenue of $1.4B in FY2025 versus $748M in FY2021, a compound +17.1%/yr. Reported net income was $178M in FY2025, compounding +186.9%/yr from FY2021.
Is PEN fairly valued? → Check now
Recent news
- Top Stock Reports for Microsoft, Exxon Mobil & Dell
- Spotting Winners: Merit Medical Systems (NASDAQ:MMSI) And Medical Devices & Supplies - Cardiology, Neurology, Vascular Stocks In Q1
- GMED vs. PEN: Which Stock Should Value Investors Buy Now?
- Penumbra Receives CE Nod for THUNDERBOLT: Stock to Gain?
External third-party headlines (Yahoo Finance, Reuters and others) — not an editorial selection, not financial advice.
Similar stocks
6 more Medical Devices stocks, each showing price versus our Fair Value estimate (as of Jun 24, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| ABT ABT | 1,600 MXN | 82.40 MXN | -95% |
| Abbott Laboratories, ABTT34 | R$37.76 | R$6.34 | -83% |
| Stryker Corporation S1YK34 | R$79.18 | R$43.78 | -45% |
| Medtronic plc MDT | $80.25 | $74.40 | -7% |
| Boston Scientific Corporation B1SX34 | R$247.01 | R$234.82 | -5% |
| Edwards Lifesciences Corporation EW | $85.88 | $41.02 | -52% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Penumbra, Inc (PEN) undervalued?
What is the fair value of PEN?
What is the quality score of PEN?
What is the revenue of Penumbra, Inc (PEN)?
What is the net profit margin of PEN?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.